Genentech
Genentech articles from Informachine.Genentech rejects Roche’s $43.7-billion takeover offer as too low
13 Aug 2008
Biotechnology giant Genentech Inc today rejected a $43.7-billion takeover bid from its majority shareholder, Roche Holding AG, as too low, while saying it would be open to a higher proposal.
Stay ahead with Informachine News Trackers! Follow your selected sources, track business news with relevant keywords, and organize seamlessly using labels and bookmarks.
Get the business updates you need, fast, focused, and tailored just for you. Save time, stay informed, and never miss a beat!
Latest articles on Genentech from Informachine
Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026
21 Oct 2026
Genentech will present new Phase III data across its neuroimmunology portfolio at MSToronto2026, including research on fenebrutinib, an investigational BTK inhibitor, and Ocrevus for people living wit
Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio
19 Oct 2026
Phase III Krascendo 1 results demonstrated divarasib’s superiority over first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung cancer
FDA Approves First-In-Class IL-6R Inhibitor as The First And Only At-Home Subcutaneous Treatment Option For Thyroid Eye Disease (TED)
16 Oct 2026
Access media kits and related information for our featured news stories.
FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
16 Oct 2026
FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favorable
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
11 Oct 2026
In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks.
FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for The Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
09 Oct 2026
FDA approval is based on results from the landmark Phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurr
Genentech and Breastcancer.Org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends
01 Oct 2026
More than 225,000 women in the U.S. are expected to be diagnosed with hormone receptor HR+, HER2- breast cancer this year, the most common form of the disease, representing approximately 70% of cases
Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions
01 Oct 2026
New real-world results for Vabysmo in wet AMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals
Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-Positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
01 Oct 2026
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus
Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
30 Sep 2026
The filing acceptance for fenebrutinib, an investigational BTK inhibitor, is based on data from the comprehensive clinical program, including the Phase III FENhance 1 and 2 RMS studies and the Phase III FENtrepid PPMS study.
